EP4286510A4 - ORAL VACCINE AGAINST CORONAVIRUS INFECTION - Google Patents

ORAL VACCINE AGAINST CORONAVIRUS INFECTION Download PDF

Info

Publication number
EP4286510A4
EP4286510A4 EP22745867.6A EP22745867A EP4286510A4 EP 4286510 A4 EP4286510 A4 EP 4286510A4 EP 22745867 A EP22745867 A EP 22745867A EP 4286510 A4 EP4286510 A4 EP 4286510A4
Authority
EP
European Patent Office
Prior art keywords
vaccine against
oral vaccine
coronavirus infection
against coronavirus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22745867.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4286510A1 (en
Inventor
Toshiro Shirakawa
Shunpei UENO
Koichi Kitagawa
Akihiko Kondo
Masanori KAMEOKA
Takane Katayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobe University NUC
Kyoto University NUC
Original Assignee
Kobe University NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobe University NUC, Kyoto University NUC filed Critical Kobe University NUC
Publication of EP4286510A1 publication Critical patent/EP4286510A1/en
Publication of EP4286510A4 publication Critical patent/EP4286510A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP22745867.6A 2021-01-26 2022-01-25 ORAL VACCINE AGAINST CORONAVIRUS INFECTION Withdrawn EP4286510A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021010009 2021-01-26
PCT/JP2022/002677 WO2022163647A1 (ja) 2021-01-26 2022-01-25 経口コロナウイルス感染症ワクチン

Publications (2)

Publication Number Publication Date
EP4286510A1 EP4286510A1 (en) 2023-12-06
EP4286510A4 true EP4286510A4 (en) 2024-12-25

Family

ID=82654588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22745867.6A Withdrawn EP4286510A4 (en) 2021-01-26 2022-01-25 ORAL VACCINE AGAINST CORONAVIRUS INFECTION

Country Status (5)

Country Link
US (1) US20240091342A1 (enrdf_load_stackoverflow)
EP (1) EP4286510A4 (enrdf_load_stackoverflow)
JP (1) JPWO2022163647A1 (enrdf_load_stackoverflow)
CN (1) CN116829693A (enrdf_load_stackoverflow)
WO (1) WO2022163647A1 (enrdf_load_stackoverflow)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2479270A1 (en) * 2009-09-17 2012-07-25 Morishita Jintan Co., Ltd. Gene expressing a bifidobacterium surface-presented fusion protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526403A (ja) * 2003-06-04 2006-11-24 バイオリーダーズ コーポレーション Ｓａｒｓウイルス抗原の細胞表面発現ベクター及びこのベクターにより形質転換された微生物
KR102292523B1 (ko) 2010-04-02 2021-08-20 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
WO2013151706A2 (en) * 2012-04-06 2013-10-10 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
CN105073989A (zh) * 2013-02-19 2015-11-18 国立大学法人神户大学 免疫原性多肽表层表达双歧杆菌
WO2016208332A1 (ja) * 2015-06-25 2016-12-29 国立大学法人神戸大学 経口腫瘍ワクチン
CN111944837B (zh) * 2020-03-30 2023-09-08 河南师范大学 一种表达covid-19抗原的表达载体及基因工程乳酸菌口服疫苗的构建方法
CN111671890B (zh) * 2020-05-14 2022-08-05 苏州大学 一种新型冠状病毒疫苗及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2479270A1 (en) * 2009-09-17 2012-07-25 Morishita Jintan Co., Ltd. Gene expressing a bifidobacterium surface-presented fusion protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KITAGAWA KOICHI ET AL: "Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-[alpha], Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice", VIRAL IMMUNOLOGY., vol. 30, no. 3, 1 April 2017 (2017-04-01), US, pages 196 - 203, XP093223657, ISSN: 0882-8245, DOI: 10.1089/vim.2016.0111 *
See also references of WO2022163647A1 *
WU KAI ET AL: "mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants", BIORXIV, 25 January 2021 (2021-01-25), XP055981165, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1.full.pdf> [retrieved on 20221114], DOI: 10.1101/2021.01.25.427948 *

Also Published As

Publication number Publication date
US20240091342A1 (en) 2024-03-21
EP4286510A1 (en) 2023-12-06
CN116829693A (zh) 2023-09-29
JPWO2022163647A1 (enrdf_load_stackoverflow) 2022-08-04
WO2022163647A1 (ja) 2022-08-04

Similar Documents

Publication Publication Date Title
EP4135847A4 (en) Coronavirus vaccine
GB202004974D0 (en) Coronavirus vaccine
EP4313143A4 (en) Coronavirus vaccine formulations
GB202004493D0 (en) Coronavirus vaccine
EP4164687A4 (en) IMPROVED CORONAVIRUS VACCINE
EP4159234A4 (en) VACCINE AGAINST SARS-COV-2
JP1733010S (ja) 歯科用器具
EP4185323A4 (en) AAV5 VACCINE AGAINST SARS-CoV-2
JP1763741S (ja) 口腔洗浄器
EP3920837C0 (en) ORAL CARE DEVICE
EP4204001A4 (en) HUMAN CYTOMEGALOVIRUS VACCINE
EP4286510A4 (en) ORAL VACCINE AGAINST CORONAVIRUS INFECTION
EP4017315A4 (en) ORAL CARE INSTRUMENT
EP4267180A4 (en) Coronavirus vaccine
IL285618A (en) Vaccine adjuvants and formulations
EP4362868A4 (en) Phacoemulsification handpiece
EP4316515A4 (en) Influenza vaccine
EP4272691A4 (en) DENTAL IMPLANT
EP4233776C0 (en) DENTAL HANDPIECE
EP4157142C0 (en) ORAL TREATMENT DEVICE
EP3914293A4 (en) Vaccination against coronavirus with poliomyelitis vaccine
IT202200007994A1 (it) Cannula odontoiatrica
EP4197484C0 (en) DENTAL HANDPIECE
EP4433112A4 (en) PORTABLE HAND-OPERATED ORAL VACUUM
EP4404917A4 (en) RNA VACCINES AGAINST INFECTIOUS DISEASES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230807

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240429

A4 Supplementary search report drawn up and despatched

Effective date: 20241126

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/62 20060101ALI20241120BHEP

Ipc: C12N 15/50 20060101ALI20241120BHEP

Ipc: C12N 15/31 20060101ALI20241120BHEP

Ipc: C07K 19/00 20060101ALI20241120BHEP

Ipc: C07K 14/195 20060101ALI20241120BHEP

Ipc: C07K 14/165 20060101ALI20241120BHEP

Ipc: A61P 37/04 20060101ALI20241120BHEP

Ipc: A61P 31/14 20060101ALI20241120BHEP

Ipc: A61K 39/215 20060101ALI20241120BHEP

Ipc: A61K 35/745 20150101ALI20241120BHEP

Ipc: C12N 1/21 20060101AFI20241120BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20250414